Pfizer is now offering an orally administered drug for those who have tested positive for COVID-19 in the past 3-5 days. Eligible participants of this study, with a confirmed diagnosis of COVID-19 (SARS-CoV-2), will be placed in two groups (1:1). Each group will receive an investigational antiviral drug or the placebo, every 12 hours for 5 days (10 doses total).
- Must be at least 19 years old
- Have initial onset of signs/symptoms attributable to COVID-19
- A confirmed SARS-CoV-2 (COVID-19) test
- Other criteria may apply*
Eligible candidates will be compensated for time and travel.